http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 10 Jul 2026 19:41:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Marks+Gilbert+Lynn/26758273.html si-local-file:///var/storage/secattach/20260710/26758273.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Marks+Gilbert+Lynn/26758273.html Fri, 10 Jul 2026 19:41:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Marks+Gilbert+Lynn/26758273.html si-local-file:///var/storage/secattach/20260710/26758273.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Marks+Gilbert+Lynn/26758273.html Fri, 10 Jul 2026 19:41:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Aziz+Kabeer/26758274.html si-local-file:///var/storage/secattach/20260710/26758274.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Aziz+Kabeer/26758274.html Fri, 10 Jul 2026 19:41:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Aziz+Kabeer/26758274.html si-local-file:///var/storage/secattach/20260710/26758274.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Aziz+Kabeer/26758274.html Fri, 10 Jul 2026 19:41:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Martin+Patricia+A./26758272.html si-local-file:///var/storage/secattach/20260710/26758272.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Martin+Patricia+A./26758272.html Fri, 10 Jul 2026 19:40:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Martin+Patricia+A./26758272.html si-local-file:///var/storage/secattach/20260710/26758272.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+10++Filed+by%3A+Martin+Patricia+A./26758272.html Fri, 10 Jul 2026 19:40:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+08++Filed+by%3A+Eizen+Joshua+M/26758191.html si-local-file:///var/storage/secattach/20260710/26758191.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+08++Filed+by%3A+Eizen+Joshua+M/26758191.html Fri, 10 Jul 2026 18:16:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+08++Filed+by%3A+Eizen+Joshua+M/26758191.html si-local-file:///var/storage/secattach/20260710/26758191.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jul+08++Filed+by%3A+Eizen+Joshua+M/26758191.html Fri, 10 Jul 2026 18:16:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+03/26619556.html si-local-file:///var/storage/secattach/20260609/26619556.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+03/26619556.html Tue, 09 Jun 2026 06:01:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+03/26619556.html si-local-file:///var/storage/secattach/20260609/26619556.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+03/26619556.html Tue, 09 Jun 2026 06:01:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+04/26605930.html si-local-file:///var/storage/secattach/20260604/26605930.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+04/26605930.html Thu, 04 Jun 2026 16:16:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+04/26605930.html si-local-file:///var/storage/secattach/20260604/26605930.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+04/26605930.html Thu, 04 Jun 2026 16:16:00 -0400 ANTX O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.</p> <p>In a nonhuman primate study, 28 days of AN2-502998 treatment eliminated parasites in 100% of animals naturally infected with Trypanosoma cruzi at target exposures planned for humans. The elimination remained durable through four months following treatment completion.</p> <p>A Phase 1 first-in-human study showed the drug was generally well tolerated with no dose-limiting toxicities. Human plasma exposures at or above the efficacy thresholds observed in the primate study were achieved.</p> <p>The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html Thu, 04 Jun 2026 07:01:02 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.</p> <p>In a nonhuman primate study, 28 days of AN2-502998 treatment eliminated parasites in 100% of animals naturally infected with Trypanosoma cruzi at target exposures planned for humans. The elimination remained durable through four months following treatment completion.</p> <p>A Phase 1 first-in-human study showed the drug was generally well tolerated with no dose-limiting toxicities. Human plasma exposures at or above the efficacy thresholds observed in the primate study were achieved.</p> <p>The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html Thu, 04 Jun 2026 07:01:02 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.</p> <p>In a nonhuman primate study, 28 days of AN2-502998 treatment eliminated parasites in 100% of animals naturally infected with Trypanosoma cruzi at target exposures planned for humans. The elimination remained durable through four months following treatment completion.</p> <p>A Phase 1 first-in-human study showed the drug was generally well tolerated with no dose-limiting toxicities. Human plasma exposures at or above the efficacy thresholds observed in the primate study were achieved.</p> <p>The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html Thu, 04 Jun 2026 07:01:02 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.</p> <p>In a nonhuman primate study, 28 days of AN2-502998 treatment eliminated parasites in 100% of animals naturally infected with Trypanosoma cruzi at target exposures planned for humans. The elimination remained durable through four months following treatment completion.</p> <p>A Phase 1 first-in-human study showed the drug was generally well tolerated with no dose-limiting toxicities. Human plasma exposures at or above the efficacy thresholds observed in the primate study were achieved.</p> <p>The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html Thu, 04 Jun 2026 07:01:02 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+May+29++Filed+by%3A+Williams+Sarah+Joanne/26592279.html si-local-file:///var/storage/secattach/20260602/26592279.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+May+29++Filed+by%3A+Williams+Sarah+Joanne/26592279.html Tue, 02 Jun 2026 16:32:00 -0400 ANTX O.53806153